ImmuPharma PLC (LON:IMM) – BUY*: Appointment of Northland as Nomad
Market Cap: £57m; Current Price: 46p; Target Price: 171p
Appointment of Northland Capital Partners Ltd. as Nominated Adviser
ImmuPharma PLC announced that it has appointed Northland Capital Partners Ltd. as its Nominated Adviser and sole broker with immediate effect.
NORTHLAND CAPITAL PARTNERS VIEW: ImmuPharma is currently completing a Phase 3 clinical trial which is expected to read-out top line results before the end of 2017. The drug has been looked upon favourably by US regulators, which have deemed it a priority treatment. Should the drug be approved, we estimate it could achieve multi-billion dollar annual sales. BUY.